Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

The conference’s abstract drop features ASC4First in its plenary session.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

The company scraps its lead project and clears out its C-suite, but there was already a precedent.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

The company dribbles out more data on IMA203, and the numbers head in the right direction.

ASCO is fast approaching, but in the meantime Olema will have an important readout.